MedTrace Logo

Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome

NCT00839228 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-11-05

No results posted yet for this study

Summary

Up to half of all patients with clinical features of heart failure are found to have normal heart pumping function. Recently the investigators have shown that a drug called perhexiline markedly improved exercise capacity and symptoms in patients with heart failure associated with impaired cardiac pump function. In this proposal the investigators will assess whether perhexiline has beneficial effects in patients with heart failure and a normal heart pumping function.

Conditions

  • Diastolic Heart Failure

Interventions

DRUG

Perhexiline

100mg o bd for 3 months

DRUG

Placebo

Placebo one tablet bd for 3 months

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Michael P Frenneaux, MBBS MD · University of Aberdeen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839228 on ClinicalTrials.gov